Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Virta now commits to stopping these increases completely, delivering 0% GLP-1 utilization growth for employers offering this drug class for obesity, while also guaranteeing strong weight loss outcomes
It works particularly well for people who have tried dietary changes and exercise without achieving sustainable results, who have been curious about Ozempic or Wegovy but found the brand-name cost prohibitive, or who prefer a structured program with physician support rather than self-directed supplementation
People who have lost large amounts of weight may experience a combination of excess skin in many different areas, such as the midsection, hips, thighs, and lower back
A novel target gene for obesity (HOOK1) was selected based on open chromatin regions along with differential gene expression levels in the discovery cohort used for the previously generated in-house datasets
US$ 23.76
US$ 21.02
US$ 22.71
US$ 21.07
US$ 21.72
US$ 28.53
US$ 25.86
US$ 22.70
